<?xml version="1.0" encoding="UTF-8"?>
<p id="para0022">Data from a phase 3 randomized controlled trial of anakinra (Kineret
 <sup>TM</sup>) in sepsis, showed significant increase in survival in patients with hyperinflammation, without increased adverse events 
 <xref rid="bib0024" ref-type="bibr">[24]</xref>. Currently, Swedish Orphan Biovitrum has an open-label, multicenter clinical trial evaluating the use of anakinra in combination with emapalumab at reducing hyperinflammation in severe COVID-19 patients. Patients in the anakinra arm, will receive anakinra intravenous (IV) infusion four times daily for 15 days (400 mg/day, divided in four daily doses).
</p>
